Abstract：Objective To study the clinical application of Compass system,a novel 3D quality assurance system for the verification of esophageal carcinoma intensity-modulated radiotherapy (IMRT) plan. Methods 12 esophageal carcinoma IMRT plans were optimized with Eclipse 8.6 treatment planning system (TPS),and then Compass reconstructed 3D dose distributions with the patient anatomy. Comparison was performed among the reconstructed and calculated with TPS, Dose-volume parameters (γ pass rate、 average dose deviation) to the planning target volume (PTV) and critical structures were quantitative valuated. Furthermore two-dimensional dose verification were performed use MatriXX,γ pass rate were evaluated with 3%/3 mm criteria. Results The γ pass rate of actual gantry angle was found generally declined seemingly compared with 0 degree gantry angle in two dimensional verification,difference was statistically significant (P=0.018-0.001).In 3D dose verification,the γ volume of PTV were exceed 93%, the deviation of D95, D50, D2 were less than 3%;The γ volume of lungs and heart were exceed 95%, the average dose deviation were less than 3%;The γ pass rate of spinal cord and trachea were exceed 98%. The independent check verified more conformed with the TPS calculated. Dose deviations appeared in the radiation field edge area. Conclusions 3D dose verification can provide more information to comprehensively evaluate the plan which is benefit for evaluating the clinical value of verification.
Xing Xiaofen,Chu Xuegang,Zheng Xuliang et al. A clinical application research of 3D dose verification for esophageal carcinoma intensity-modulated radiation therapy with Compass[J]. Chinese Journal of Radiation Oncology, 2015, 24(3): 327-330.
[1] Bortfeid T,Boyer AL,Schlegel W, et al. Realization and verification of three dimensional conformal radiotherapy with modulated fields[J].Int J Radiat Oncol Biol Phys,1994,30(4):899-908. [2] Tsai JS,Wazer DE,Ling MN,et al. Dosimetrie verification of the dynamic intensity-modulated radiation therapy of 92 patients[J].Int J Radjat Oneol BiolPhys,1998,40(5):1213-1230. [3] Nelms BE1, Zhen H, Tomé WA.Per-beam, planar IMRT QA passing rates do not predict clinically relevant patient dose errors[J]. Med Phys,2011,38(2):1037-1044.DOI:10.1118/1.3544657. [4] Godart J, Korevaar EW, Visser R, et al. Reconstruction of high-resolution 3D dose frommatrix measurements:error detection capability of the COMPASS correction kernel method[J]. Phys Med Biol,2011,56(15):5029-5043.DOI:1088/0031-9155/56/15/023. [5] Boggula R, Jahnke L,Wertz H,et al. Patient-specific 3D pretreatment and potential 3D online dose verification of montecarlocalcuiated IMRT prostate treatment plans[J]. Int J Radiat Oncol Biol Phys,2011,81(4):1168-1175.DOI:10.1016/j.ijrobp.2010.09.010. [6] ICRU. Prescribing, recording and reporting photon-beam intensity-modulated radiation therapy. ICRU Report 83[S].Oxford:Oxford University Press,2010. [7] van Zijtveld M, Dirkx ML, de Boer HC,et al. 3D dose reconstruction for clinical evaluation of IMRT pretreatment verification with an EPID[J].Radiother Oncol,2007,82(2):201-207. [8] Schreibmann E, Dhabaan A, Elder E,et al. Patient-specific quality assurance method for VMAT treatment delivery[J].Med Phys,2009,36(10):4530-4535. [9] 沈文斌,祝淑钗,李任,等.胸中下段食管癌三维适形放疗所致放射性肺损伤相关因素分析[J].中华放射肿瘤学杂志,2007,16(5):335-339. [10] Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for peneumenitis 3D treatment for non-small cell lung cancer (NSCLC)[J]. Int J Radiat Oncol Biol Phys,1999,45(2):323-329. [11] Jenkins P, Amico KD, BensteadK,et al. Radiation pneumonitis following treatment of non-small cell lung cancer with continuous hyperfractionated accelerated radiotherapy[J]. Int J Radiat Oncol Biol Phys,2003,56(2):360-366.
2015, Vol. 24 
